<DOC>
	<DOCNO>NCT00772655</DOCNO>
	<brief_summary>This European multicenter study 90Yttrium-Ibritumomab Tiuxetan ( 90Y-Ibritumomab Tiuxetan ) ( Zevalin® ) front line therapy patient follicular lymphoma grade I-IIIa stage III-IV ( well select patient extend abdominal stage II ) . For patient complete clinical remission persistent molecular disease subsequent 90Y-Ibritumomab Tiuxetan treatment consolidation immunotherapy Rituximab add , eradicate minimal residual disease .</brief_summary>
	<brief_title>Zevalin® First Line Follicular Lymphoma</brief_title>
	<detailed_description>Only patient require treatment ( B-symptoms , lymphoma progression &gt; 50 % within observation period 6 month less , organ compression lymphoma bulky disease define lesion 5 cm one axis ) may enter study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient &gt; 50 year old Follicular lymphoma grade I , II , IIIa accord REAL/WHO classification Ann Arbor stage III , IV , stage II disseminate abdominal disease require extensive abdominal irradiation No prior chemotherapy , immunotherapy , irradiation . Furthermore , receive therapy part `` Zevalin® first line follicular lymphoma '' trial six month therapy end , patient may participate another clinical trial . If patient receive consolidation therapy Rituximab , six month period count end consolidation therapy . Lymphoma cell positive CD20 Measurable disease ( two perpendicular diameter either physical radiological examination ) WHO/ECOG performance status 0 2 Written inform consent Bone marrow involvement Bone marrow infiltration &gt; 25 % Leukocytopenia &lt; 2.500 /µl Thrombocytopenia &lt; 100.000 /µl Bulk lesion &gt; 10 cm CNS lymphoma manifestation Circulating tumor cell &gt; 500 /µl Extensive pleural effusion/ascites ( &gt; 1000 ml estimate ultrasound/CT ) Severe concomitant disease ( e.g . congestive heart failure , myocardial infarction within 6 month study , severe uncontrolled hypertension , renal insufficiency require hemodialysis , pulmonary disease , liver disease ) Abnormal liver function : transaminase total bilirubin &gt; 2 x upper limit normal ( ULN ) ( unless cause lymphoma ) Abnormal renal function : serum creatinine &gt; 2 x upper limit normal ( unless cause lymphoma ) Previous malignancy nonmelanoma skin cancer Pregnant breast feed female patient ( negative pregnancy test require woman fertile age ) , effective contraception HIV positivity Known hypersensitivity foreign protein , murine antibody , presence human antimurine antibody ( HAMA ) reactivity Severe psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>First line therapy</keyword>
	<keyword>Zevalin</keyword>
	<keyword>90Yttrium-Ibritumomab Tiuxetan</keyword>
	<keyword>Yttrium</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Radio-immuno therapy</keyword>
</DOC>